Medical Physics Aspects of Radiotherapy with lons

Physics technologies in medicine (4/4)

CERN, Geneva


January 2005

PD Dr Oliver Jäkel Dep. for Medical Physics German Cancer Research Center



Hadrons in radiation therapy

Comparisons of protons, neutrons, pions, ions, photons




Medical Physics

Page 2

PD Dr. Oliver Jäkel

dkfz.


Depth dose distributions of hadron beams



- Neutrons are very similar to photons in terms of depth dose
- Ions show reduced entrance dose and no/little dose behind the Bragg peak



Lateral scattering of carbon ions vs. protons




Page 4



The Rationale for Conformal Radiation Therapy

- Dose limitation (and TCP-Limitation) due to tolerance of OAR
- Volume effect: increase of tolerance if smaller volume irradiated



Dosis


Better conformation of dose enables application of higher doses & higher tumor control without increasing normal tissue complication rate

Medical Physics






Radiobiology of high and low LET radiation



Damage in nucleus



High LET

Local deposition of high doses


M. Scholz et al. Rad. Res. 2001 Immunoflourescence image of the repair protein p21;


Medical Physics



Passive beam shaping (standard method)

Range modulator wheel






Medical Physics

TPS for passive beam shaping

Patient specific hardware needed:


- Optimization of Spread Out Bragg Peak, compensator and collimator
- Setup errors of all elements must be considered



- Only measured depth doses needed
- No detailled biological modelling needed




Ridge filter design and SOBP for HIMAC





3D Active beam scanning at GSI

- Energy variation of synchrotron (~1mm resolution depth)
- Intensity controlled raster scanning (~2 mm, 5mm fwhm)




Optimization if typically 30-50 energies, 20 000 -50 000 field spots


Medical Physics



3D active beam shaping (protons: PSI, ions: GSI)

- No patient specific hardware
- Fragmentation model needed
- Biological modelling needed






Single Bragg peaks Variable energy Scanning or MLC Dose conformation also at proximal end



Calculation of biological effective dose (ions)




- Account for nuclear fragmentation in every point in 3D
- Detailled biological modelling necessary




Biological treatment planning for carbon ions


Physical dose of single fields



Local effect model of Scholz and Kraft: Calculation of RBE as a 3D distribution Input: X-ray survival curves & fragmentation spectra











Empirical range calculation from CT numbers

- Tissue equivalent phantoms
- Real tissue measurements











Possible distortions of CT numbers





Contrast agent in CT

- mean shift (25 pat.): 18 HU
- max shifts: 36 HU
- Errors in range < 1.6 %


Reconstruction filters

- redistribution of HU numbers
- Errors in range < 3 %


Special attention to QA of the CT and imaging protocols !



Metal artifacts in CT images



- Artefacts from gold fillings or implants
- Simulation of effects of wrong HU
- Uncertainty in range calculation
- Some patient may be rejected
- Gold fillings have to be removed






Uncertainties in Range due to misalignment

Wrong patient position changes the tissue traversed by the beam and may lead to over/underdosages:

Effect of a 5mm cranial shift on the particle ranges:




The robustness of treatment plans has to be tested!

Page 17


Medical Physics









In vivo monitoring with PET for ions



PET – Monitoring in situ Patient with Chondrosarcoma of skull base





Dose distribution carbon ions

PET-Measurement

Page 20

PD Dr. Oliver Jäkel

Medical Physics




Dose verification for active beam delivery

Problem:

- Scanning chambers for dynamic fields not suitable
- Simulateous measurement of many channels

Verification phantom:


- 24 Pinpoint chambers
- Readout by 2 Multidos-Dosemeters
- Computer controlled movement of the chambers in the water phantom





Verification software

- Interface to therapy planning
- Display dose in water
- Display of chamber positions




- Measurement at 24 positions
- Comparison w. therapy planning
- Analysis and documentation

		i <mark>fication of dyna</mark> Dose cube Wi	mically gene aterphantom	erated 3D d Help	ose distrib	utions - V	1.4				
Dete: 23. February 1999–21:52 Connected: Multidos I and Multidos II Protocol: D:∖dosis∖doc∖cjz105_04.dat IC chamber: IC03/13-24 : calibrated / IC03/13-24 : calibrated					Correction: Enabled kd=1.034 kq=1.028 Background correction: Enabled (21.41 on 23.02.1999) Mode: Dose [Gy] Range: Low						
Comment											
IC	Status	Dose [Gy]	TPD [Gy]	StdDev [Gy]] Dev [%]	IC	Status	Dose [Gy]	TPD [Gy]	StdDev [Gy]	Dev [%]
1	OK	146.8E-03	0.159	0.00	-5.2	I 13	OK	180.3E-03	0.193	0.00	-5.7
₽ 2	OK	200.1E-03	0.203	0.00	-1.1	₩ 14	OK	174.8E-03	0.182	0.00	-3.1
V 3	ОК	154.6E-03	0.169	0.00	-6.2	IT 15	OK	167.3E-03	0.164	0.00	1.7
▼ 4	OK	125.6E-03	0.139	0.00	-5.8	F 16	inactive	171.7E-03	0.157	0.01	6.8
5	inactive	148.7E-03	0.147	0.00	0.9	IT 17	OK	189.2E-03	0.202	0.00	-5.5
6	OK	202.7E-03	0.206	0.00	-1.3	IN 18	OK	186.4E-03	0.190	0.00	-1.6
₽ 7	OK	203.5E-03	0.210	0.00	-2.8	IT 19	OK	177.0E-03	0.178	0.00	-0.4
8 되	OK	189.6E-03	0.196	0.00	-2.9	IZ 20	OK	164.3E-03	0.172	0.00	-3.7
9	OK	157.3E-03	0.168	0.00	-4.6	IZ 21	OK	160.9E-03	0.169	0.00	-3.4
[10	inacti∨e	88.0E-03	0.058	0.01	13.6	I 22	OK	184.6E-03	0.189	0.00	-1.8
II 🗹	ОК	193.4E-03	0.200	0.00	-2.8	₽ 23	OK	147.7E-03	0.159	0.00	-4.9
I 2	ОК	210.4E-03	0.211	0.00	-0.3	₽ 24	OK	27.8E-03	0.025	0.00	1.4
Ste	art	Hold	Reset	1	ntegrate	Multidos Multidos		Time: 323.5s Time: 323.5s	Error: OK Error: OK		
Phantom: waterA Sta				Standard devi	in deviation: -2.9 % X-coordinate: 0.0 mm H2 idard deviation: 2.3 % Y-coordinate: -15.0 mm iber of active ICs: 21 Z-coordinate: -63.5 mm			m H2O			


Verification of therapy plans prior to first application



Carbon Ion Dose Determination



$$k_{Q,Q_{o}} = \frac{\begin{pmatrix} w_{air} \\ e \end{pmatrix}^{^{12}C}}{\begin{pmatrix} w_{air} \\ e \end{pmatrix}^{^{60}Co}} \cdot \frac{\overline{s}_{w,air}^{^{12}C}}{(\overline{L} / \rho)_{w,air}^{^{60}Co}} \cdot \frac{p^{^{12}C}}{p^{^{60}Co}}$$




Spencer-Attix Stopping Power Ratio

$$\overline{S}_{w,air} = \frac{\sum_{i} \int_{0}^{\infty} \Phi_{E,i} (S_i(E) / \rho)_w dE}{\sum_{i} \int_{0}^{\infty} \Phi_{E,i} (S_i(E) / \rho)_{air} dE}$$

Parameter	$\left(w/e\right)^{^{12}C}$	$(w/e)^{60}Co$	$S_{w,air}^{^{12}C}$	$(\overline{L}/ ho)^{^{60}Co}_{w,air}$	$p^{^{60}Co}$	$p^{^{12}C}$
Uncertainty	1.5 - 4%	0.2%	2.0%	0.5%	0.6%	1%?




Stopping power ratio water/air for C12 averaged over fragment spectrum






Energy spectrum of a 360 MeV/u C12 in water close to Bragg peak (Monte Carlo)





Biological Verification



- Biological planning and optimization for CHO Zellen
- Calculation of cell survival
- Irradiation of stack with probes of cells
- every time consuming

Krämer et al. Phys Med Biol. 48: 2063-70, 2003

Medical Physics



Application in clinical studies at GSI Skull base chordoma and chondrosarcoma

Fully fractionated therapy, 60 Gye in 20 fractions 8/98 - 12/01: 67 patients treated in phase I/II studies since 3/02: approval to use HIRT as standard therapy (~55 pat.)

Adenoidcystic Carcinoma and atypical meningeoma

Carbon ion boost after conventional therapy or IMRT 18 Gye in 6 fractions HI + 54 Gy photons 3/00 - 8/04: ~45 patients in phase I/II studies

Pelvic and spinal chordoma and chondrosarcoma

Carbon ion boost after conventional therapy or IMRT 18 Gye in 6 fractions HI + 54 Gy photons 6/00 - 8/04: ~22 patients in phase I/II studies



Clinical Outcome of patient treatments @ GSI Status 2 / 2003

Indication	#	follow-up	act. LC	3y Surv.	Side effects
Chord. SB	54	20m	81% (3y)	91%	<= 3° CTC
Ch.sarc. SB	33	20m	100% (3y)	0170	<= 3° CTC
Sacral Chord.	8	~22m	7(8) pat.	7(8)	none
Cervical Ch/C	S 9	~22m	8(9) pat.	8(9)	<= 3° CTC
ACCa	21	14m	62%(3y)	75%	<= 3° CTC


- Outcome for ACC: 75% vs. 24% after Photon IMRT, while severe side effects (< °2 CTC) are < 5% (vs >10% for neutron RT) !


- No severe late effects (>2° CTC) of spinal chord were observed
- ~ 30 patients treated outside protocols (palliative, re-irradiation)

Page 28



Clinical application: Skull base tumor






Primary Iontherapy2 Fields60 Gye in 20 Fractions

dkfz.


Example: Recurrent Clivuschordoma

- subtotal resection 1996
- proton therapy 79.2GyE,1996
- 11/98 20.8 Gy FSRT + 27 GyE C12 at recurrency





Combination Therapy for Adenoidcystic Ca.



Fractionated radiotherapy with photons to 54 Gy to PTV


Boost treatment with carbon ions 18 Gy to GTV

Rationale:

- Normal tissue in PTV
- More robust plans
- More patients treated



IMXT vs C-12 for skull base tumors



- Lower integral dose for C-12
- Steeper dose gradients for C-12
- Reduced number of fields
- Nearly complete sparing of OAR possible




Outlook


floor plan level 99 scale 1:100

M 95908

dkfz.

- compact heavy ion synchrotron
- Isocentric gantry for ions
- p,He,C,O,... ions
- 1000 patients/yr
- In operation
 ~2006/2007





Page 34




Model of the facility





Gantry concept





Conclusion

Demonstration of feasibility + safety of scanned carbon ions in clinical routine for 230 patients

Outcome for Ch/CS of skull base comparable to protons for ACCa. as for neutrons, but only mild side effects

Good agreement of observed / predicted rate of side effects from radiobiological model

High future potential for heavy ions,

- if organ movement can be tracked online
- if Intensity modulation is at the same level of IMXT
- if clinical studies show benefit for other tumors/ions


Page 37






Stereotactic Imaging

"Fiducials" at stereotactic. ring visible in CT (Steel), MRI (Gd-DTPA), PET (Cu-64)






- Automated Detection
- Calculation of st. coordinates
- Correction of misaligned




Stereotactical Image correlation for target definition:

Brain metastasis



MRI 3d Turbo FLASH Sequence with contrast

MRI T2 weighted Spin Echo seq.




MRI Spin-Echo-Sequence




Patient Fixation and Stereotactic Positioning

Head mask and Stereotactic setup

Body frame fixation







Position control using X-rays and DRR

— HIP2 (Heavy Ion therapy Project positioning) (c) 1998 by J. Kress							
File Fields Include Utilities Left Window Right Window							
Patient: CTP046	ALCULATE High resolution High speed High resolution Low speed						
Tube L3	Tube L2						
L3, couch 180							

Accuracy for positioning around 1mm required !

Page 42

